Sep 13, 2021 / 03:45PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Great, everybody. Still good morning. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have a Alector with us for the next session.
Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/research disclosures. And with me, pleased to have Arnon Rosenthal, who's the CEO of Alector.
And Arnon, I'm going to turn it over to you to make some opening comments, and then we can get started.
Arnon Rosenthal - Alector, Inc. - Co-Founder, CEO & Director
Great. Thank you, and welcome, everyone. So Alector was created with the purpose of developing and executing a novel therapeutic strategy for dementia, neurodegeneration. And instead of going after the misfolded proteins, like A-beta and tau and alpha
Alector Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers